On February 10, 2020 TriSalus Life Sciences, a company committed to developing comprehensive solid tumor solutions, reported that Mary Szela, President and CEO, will speak on the panel, "Expanding the Toolkit for Fighting Solid Tumors" at the 2020 BIO CEO & Investor Conference in New York City (Press release, TriSalus Life Sciences, FEB 10, 2020, View Source [SID1234554098]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This panel will explore the breadth of the solid tumor-fighting pipelines and those clinical benefits likely to be realized soonest. Experience has shown that to date there has been limited success with the currently approved or experimental therapeutics in impacting solid tumors and that these often have undesirable side effects. While we have witnessed a surge of systemic therapies in recent years (For example, the check point inhibitors), the need for safer and truly effective treatment remains.

However, exciting approaches in other mechanisms of action are also expanding our understanding of solid tumors, the tumor microenvironments, and the opportunities to disrupt tumor growth and help cancer patients. "I am honored to participate in such an important panel discussion of how we can improve outcomes in solid tumors through new approaches such as TriSalus’ tri-pronged approach which combines CAR-T with an immuno-modulation agent and proprietary, intravascular delivery to treat liver metastases and pancreatic cancer," said Mary Szela, President and CEO of TriSalus.

Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies including two days of productive partnering meetings with institutional and early-stage investors, industry analysts, and senior biotechnology executives, in one location.

Mary has limited availability during the conference. If you are interested in setting up a meeting with Mary, please contact Lisa DeScenza from LaVoieHealthScience at [email protected].